➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Merck
Medtronic
Moodys

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for MT-8554


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for MT-8554?

MT-8554 is an investigational drug.

There have been 8 clinical trials for MT-8554. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2017.

The most common disease conditions in clinical trials are Hot Flashes, Peripheral Nervous System Diseases, and Pain. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Corporation, Mitsubishi Tanabe Pharma Development America, Inc., and [disabled in preview].

There are three US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for MT-8554
TitleSponsorPhase
Definitive QT Study With MT-8554Mitsubishi Tanabe Pharma Development America, Inc.Phase 1
Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor SymptomsMitsubishi Tanabe Pharma Development America, Inc.Phase 2
MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal WomenMitsubishi Tanabe Pharma Development America, Inc.Phase 2

See all MT-8554 clinical trials

Clinical Trial Summary for MT-8554

Top disease conditions for MT-8554
Top clinical trial sponsors for MT-8554

See all MT-8554 clinical trials

US Patents for MT-8554

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MT-8554   Start Trial Sulfonamide compounds having TRPM8 antagonistic activity Mitsubishi Tanabe Pharma Corporation (Osaka-shi, JP)   Start Trial
MT-8554   Start Trial Sulfonamide compound MITSUBISHI TANABE PHARMA CORPORATION (Osaka-shi, JP)   Start Trial
MT-8554   Start Trial Sulfonamide compounds having TRPM8 antagonistic activity MITSUBISHI TANABE PHARMA CORPORATION (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MT-8554

Drugname Country Document Number Estimated Expiration Related US Patent
MT-8554 Australia 2012229813 2031-03-16   Start Trial
MT-8554 Brazil 112013023330 2031-03-16   Start Trial
MT-8554 Canada 2826678 2031-03-16   Start Trial
MT-8554 China 103443080 2031-03-16   Start Trial
MT-8554 Denmark 2686302 2031-03-16   Start Trial
MT-8554 European Patent Office 2686302 2031-03-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Dow
AstraZeneca
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.